Brokerages Set Amedisys, Inc. (NASDAQ:AMED) Price Target at $100.67

Amedisys, Inc. (NASDAQ:AMED) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $100.67.

AMED has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 target price on shares of Amedisys in a research report on Thursday, July 25th. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a research report on Monday, July 29th.

Institutional Investors Weigh In On Amedisys

Several hedge funds have recently bought and sold shares of AMED. Innealta Capital LLC acquired a new stake in shares of Amedisys during the 2nd quarter valued at about $64,000. Covestor Ltd grew its holdings in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after purchasing an additional 447 shares during the period. Signaturefd LLC increased its position in shares of Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after buying an additional 530 shares in the last quarter. CWM LLC raised its stake in shares of Amedisys by 14.5% during the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after buying an additional 277 shares during the period. Finally, GAM Holding AG acquired a new position in shares of Amedisys during the 2nd quarter worth approximately $275,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of AMED opened at $95.49 on Friday. The company has a 50 day moving average of $97.04 and a two-hundred day moving average of $95.58. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys has a twelve month low of $89.55 and a twelve month high of $98.95. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -149.20, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.